LLY
Eli Lilly and Company
LLY has the edge over MYGN overall, supported by lower modeled downside and stronger fundamentals.
MYGN
Myriad Genetics, Inc.
MYGN trails on the overall score without a compensating advantage in the available component scores.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
MYGN Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Under pressure | |
| Under pressure | |
| Under pressure |
MYGN's revenue is currently stable, but its profitability, cash flow and balance sheet are under pressure.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
MYGN PE Valuation
MYGN has no meaningful PE right now: it lost money over the past year.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
LLY has the edge over MYGN on the outlook, with more favorable earnings and revenue expectations.
MYGN Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Decline | |
| Strongly weakening | |
| Limited | |
| Low |
Analysts expect MYGN's losses to grow, with revenue declining. However, they disagree widely on these estimates.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over MYGN on earnings quality, reporting a profit while its opponent remains loss making.
MYGN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.37 | +$2.96 |
| Q2 2026 | -$1.20 | +$3.08 |
| Q1 2026 | -$4.31 | -$3.19 |
| Q4 2025 | -$3.95 | -$2.54 |
| Q3 2025 | -$4.33 | -$3.05 |
| Q2 2025 | -$4.28 | -$2.49 |
| Q1 2025 | -$1.12 | +$1.68 |
| Q4 2024 | -$1.41 | +$1.77 |
MYGN is still losing money, but far less than before: $1.37 per share over the past year, against $4.33 at its worst in late 2025.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over MYGN on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over MYGN on profitability, with a higher operating margin.
MYGN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $202.7M | -1.5% |
| Q2 2026 | $190.7M | -11% |
| Q1 2026 | $200.4M | +2.3% |
| Q4 2025 | $209.8M | -0.4% |
| Q3 2025 | $205.7M | -3.6% |
| Q2 2025 | $213.1M | +0.8% |
| Q1 2025 | $195.9M | -3.1% |
| Q4 2024 | $210.6M | +7.1% |
MYGN's revenue grew through 2023 and has held roughly level since: $203M last quarter, down 1.5% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -20% | -8.3 points |
| Q2 2026 | -20% | +134 points |
| Q1 2026 | -15% | -0.5 points |
| Q4 2025 | -2.7% | +16 points |
| Q3 2025 | -11% | -1.9 points |
| Q2 2025 | -154% | -137 points |
| Q1 2025 | -15% | -1 points |
| Q4 2024 | -19% | -2.5 points |
MYGN's operating margin was −20% last quarter, down 8.3 points from the same quarter a year ago.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over MYGN on cash generation, producing positive trailing cash flow while its opponent burns cash.
MYGN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$6.5M | -131% |
| Q2 2026 | -$8.3M | +$5.3M |
| Q1 2026 | -$15.7M | +$600K |
| Q4 2025 | $10.6M | +61% |
| Q3 2025 | $21.1M | +2914% |
| Q2 2025 | -$13.6M | -623% |
| Q1 2025 | -$16.3M | +$2.3M |
| Q4 2024 | $6.6M | +$61.3M |
MYGN has burned cash in most quarters: −$20M over the past year, against −$2M the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over MYGN on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
MYGN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +900K shares |
| 1 year | +2.8% | +2.6M shares |
| 3 years | +17% | +13.8M shares |
| 5 years | +17% | +14.2M shares |
| Available history | +29% | +21.3M shares |
MYGN has 96M diluted shares, up 2.8% from a year ago.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
MYGN Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2019 | 3.3x | Elevated |
MYGN's net debt is about 3.3 years of its operating earnings (EBITDA).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
MYGN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 57.4 | Neutral |
| Stochastic | 80.3 | Overbought |
MYGN's weekly RSI is 57 (neutral) and its Stochastic is 80 (overbought).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
MYGN PE vs Healthcare Sector
MYGN has no meaningful PE right now: it lost money over the past year.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over MYGN on trend strength, trading above more of its moving averages.
MYGN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $5.10 | 11% above |
| 20 week MA | $4.52 | 26% above |
| 50 week MA | $4.88 | 16% above |
| 100 week MA | $6.48 | 12% below |
| 200 week MA | $13.8 | 59% below |
MYGN has bounced recently, but its long-term trend is still down: it's above its 8-, 20- and 50-week averages, but 59% below its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over MYGN on returns for 2026, with the stronger performance.
MYGN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $26.8 | $18.4 | -31% |
| 2021 | $18.4 | $27.3 | +48% |
| 2022 | $27.3 | $15.6 | -43% |
| 2023 | $15.6 | $19.1 | +22% |
| 2024 | $19.1 | $13.4 | -30% |
| 2025 | $13.4 | $6.48 | -52% |
| 2026 YTD | $6.48 | $5.68 | -12% |
MYGN has finished lower in four of the last six years. It's down 12% so far in 2026.